1
|
Kuenzel WJ, Kang SW, Jurkevich A. The vasotocinergic system and its role in the regulation of stress in birds. VITAMINS AND HORMONES 2019; 113:183-216. [PMID: 32138948 DOI: 10.1016/bs.vh.2019.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The regulation of stress in birds includes a complex interaction of neural systems affecting the hypothalamic-pituitary-adrenal (HPA) axis. In addition to the hypothalamic paraventricular nucleus, a structure called the nucleus of the hippocampal commissure likewise affects the output of pituitary stress hormones and appears to be unique to avian species. Within the anterior pituitary, the avian V1a and V1b receptors were found in corticotropes. Based on our studies with central administration of hormones in the chicken, corticotropic releasing hormone (CRH) is a more potent ACTH secretagogue than arginine vasotocin (AVT). In contrast, when applied peripherally, AVT is more efficacious. Co-administration of AVT and CRH peripherally, resulted in a synergistic stimulation of corticosterone release. Data suggest receptor oligomerization as one possible mechanism. In birds, vasotocin receptors associated with stress responses include the V1a and V1b receptors. Three-dimensional, homology-based structural models of the avian V1aR were built to test agonists and antagonists for each receptor that were screened by molecular docking to map their binding sites on each receptor. Additionally, binding affinity values for each available peptide antagonist to the V1aR and V1bR were determined. An anterior pituitary primary culture system was developed to determine how effective each antagonist blocked the function of each receptor in culture when stimulated by a combination of AVT/CRH administration. Use of an antagonist in subsequent in vivo studies identified the V1aR in regulating food intake in birds. The V1aR was likewise found in circumventricular organs of the brain, suggesting a possible function in stress.
Collapse
Affiliation(s)
- Wayne J Kuenzel
- Poultry Science Center, University of Arkansas, Fayetteville, AR, United States.
| | - Seong W Kang
- Poultry Science Center, University of Arkansas, Fayetteville, AR, United States
| | - Alexander Jurkevich
- Molecular Cytology Research Core Facility, University of Missouri, Columbia, MO, United States
| |
Collapse
|
2
|
Stevenson EL, Caldwell HK. The vasopressin 1b receptor and the neural regulation of social behavior. Horm Behav 2012; 61:277-82. [PMID: 22178035 PMCID: PMC3310934 DOI: 10.1016/j.yhbeh.2011.11.009] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2011] [Revised: 11/25/2011] [Accepted: 11/28/2011] [Indexed: 12/24/2022]
Abstract
To date, much of the work in rodents implicating vasopressin (Avp) in the regulation of social behavior has focused on its action via the Avp 1a receptor (Avpr1a). However, there is mounting evidence that the Avp 1b receptor (Avpr1b) also plays a significant role in Avp's modulation of social behavior. The Avpr1b is heavily expressed on the anterior pituitary cortiocotrophs where it acts as an important modulator of the endocrine stress response. In the brain, the Avpr1b is prominent in the CA2 region of the hippocampus, but can also be found in areas such as the paraventricular nucleus of the hypothalamus and the olfactory bulb. Studies that have employed genetic knockouts or pharmacological manipulation of the Avpr1b point to the importance of central Avpr1b in the modulation of social behavior. However, there continues to be a knowledge gap in our understanding of where in the brain this is occurring, as well as how and if the central actions of Avp acting via the Avpr1b interact with the stress axis. In this review we focus on the genetic and pharmacological studies that have implicated the Avpr1b in the neural regulation of social behaviors, including social forms of aggressive behavior, social memory, and social motivation. This article is part of a Special Issue entitled Oxytocin, Vasopressin, and Social Behavior.
Collapse
Affiliation(s)
- Erica L Stevenson
- Laboratory of Neuroendocrinology and Behavior, Department of Biological Sciences and School of Biomedical Sciences, Kent State University, Kent, OH 44242,, USA
| | | |
Collapse
|
3
|
Mikhailova MV, Blansett J, Jacobi S, Mayeux PR, Cornett LE. Transmembrane domain IV of the Gallus gallus VT2 vasotocin receptor is essential for forming a heterodimer with the corticotrophin releasing hormone receptor. JOURNAL OF BIOMEDICAL OPTICS 2008; 13:031208. [PMID: 18601532 PMCID: PMC3983704 DOI: 10.1117/1.2943285] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Corticotropin releasing hormone receptor (CRHR) and the VT2 arginine vasotocin receptor (VT2R) are vital links in the hypothalamic-pituitary-adrenal axis that enable a biological response to stressful stimuli in avian species. CRHR and VT2R are both G-protein coupled receptors (GPCRs), and have been shown by us to form a heterodimer via fluorescent resonance energy transfer (FRET) analysis in the presence of their respective ligands, corticotrophin releasing hormone (CRH) and arginine vasotocin (AVT). The dimerization interface of the heterodimer is unknown, but computational analyses predict transmembrane domains (TMs) as likely sites of the interaction. We constructed chimerical VT2Rs, tagged at the C-terminal ends with either cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP), by replacing the fourth transmembrane region (TM4) of VT2R with TM4 of the beta2-adrenergic receptor (beta2AR). The VT2R/beta2AR chimeras were expressed in HeLa cells and proper trafficking is confirmed by observing cell membrane localization using confocal microscopy. VT2R/beta2AR-YFP chimera functionality was confirmed with a Fura-2 acetoxymethyl ester (Fura-2AM) assay. FRET analysis was then performed on VT2/beta2AR-chimera/CRHR pairs, and the calculated distance was observed to be >10 nm apart, indicating that heterodimerization was partly disrupted by mutating TM4 of the VT2R. Therefore, TM4 may form one region of the possible dimerization interfaces between the VT2R and CRHR.
Collapse
Affiliation(s)
- Marina V Mikhailova
- University of Arkansas for Medical Sciences, Department of Physiology and Biophysics, 4301 West Markham Street, Little Rock, Arkansas 72205, USA.
| | | | | | | | | |
Collapse
|
4
|
Syed N, Martens CA, Hsu WH. Arginine vasopressin increases glutamate release and intracellular Ca2+ concentration in hippocampal and cortical astrocytes through two distinct receptors. J Neurochem 2007; 103:229-37. [PMID: 17877638 DOI: 10.1111/j.1471-4159.2007.04737.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Arginine vasopressin (AVP), released from the CNS, plays an important role in regulating several aspects of CNS functions including aggression, anxiety, and cognition. In this study, we report a novel finding that AVP induces glutamate release from astrocytes isolated from the cerebral cortex and hippocampus. We also investigated the types of AVP receptors involved in the AVP-induced increase in glutamate release from astrocytes isolated from the hippocampus and cortex of neonatal rats. We showed that the AVP (0.1-1000 nmol/L) induced increase in glutamate release and [Ca(2+)](i) is brought about by two distinct subtypes of V(1) receptors (V(1a) and V(1b)). Our results suggested that V(1b) receptors are predominantly expressed in astrocytes isolated from the hippocampus and V(1a) receptors are solely expressed in astrocytes isolated from the cerebral cortex of neonatal rats. The results of the western blot analyses confirmed these pharmacological data. In addition, the AVP-induced increase in glutamate did not contribute to an increase in [Ca(2+)](i), as blockade of metabotropic glutamate receptors did not alter the AVP-induced increase in [Ca(2+)](i). In addition, the administration of a phospholipase A(2) inhibitor failed to alter AVP-induced [Ca(2+)](i) increase suggesting the lack of involvement of this enzyme.
Collapse
Affiliation(s)
- Nasser Syed
- Department of Biomedical Sciences and Interdepartmental Program of Toxicology, Iowa State University, Ames, Iowa, USA
| | | | | |
Collapse
|
5
|
Thibonnier M. Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opin Investig Drugs 2005; 7:729-40. [PMID: 15991964 DOI: 10.1517/13543784.7.5.729] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Vasopressin (AVP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by the stimulation of specific G-protein-coupled receptors (GPCRs) currently classified into V(1)-vascular (V(1)R), V(2)-renal (V(2)R) and V(3)-pituitary (V(3)R) AVP receptors and OT receptors (OTR). The signal transduction pathways coupled to the different subtypes of AVP/OT receptors are reviewed. The recent cloning of the different members of the AVP/OT family of receptors now allows the extensive characterisation of the molecular determinants involved in agonist and antagonist binding, as well as signal transduction coupling. Potential therapeutic uses of AVP receptor antagonists include: the blockade of V(1)-vascular AVP receptors in arterial hypertension, congestive heart failure (CHF) and peripheral vascular diseases; the blockade of V(2)-renal AVP receptors in the syndrome of inappropriate vasopressin secretion, CHF, liver cirrhosis, nephrotic syndrome and any state of excessive retention of free water and subsequent hyponatraemia; the blockade of V(3)-pituitary AVP receptors in adrenocorticotropin (ACTH)-secreting tumours. The pharmacological and clinical profile of orally-active non-peptide AVP receptor antagonists is reviewed.
Collapse
Affiliation(s)
- M Thibonnier
- Division of Clinical and Molecular Endocrinology, Case Western Reserve University School of Medicine & University Hospitals, Cleveland, Ohio 44106-4951, USA.
| |
Collapse
|
6
|
Ma S, Shipston MJ, Morilak D, Russell JA. Reduced hypothalamic vasopressin secretion underlies attenuated adrenocorticotropin stress responses in pregnant rats. Endocrinology 2005; 146:1626-37. [PMID: 15591137 DOI: 10.1210/en.2004-1368] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
We sought to explain decreased ACTH secretory responses to stress in pregnant rats by investigating hypothalamic CRH and vasopressin secretion and actions on anterior pituitary corticotrophs. In late pregnancy median eminence, CRH content was reduced (by 12%). Anterior pituitary proopiomelanocortin mRNA expression, measured by in situ hybridization but not radioimmunoassayed ACTH content, was also reduced (by 45% on d 21); CRH receptor (CRHR)1 mRNA expression was unaltered in pregnancy, but V1b receptor mRNA expression was reduced (by 19%). ACTH secretory responses, measured in jugular blood, to CRH (200 ng/kg iv) or vasopressin (1.7 microg/kg, iv) were reduced on d 21 vs. virgins (49% and 44%), but the response to combined CRH and vasopressin injection was intact. Either antalarmin (CRHR1 antagonist; 20 mg/kg ip) or dP(Tyr(Me)2),Arg-NH2(9))AVP (V1a/b antagonist; 10 microg/kg, iv) pretreatment reduced the ACTH secretory response to forced swimming (90 sec) in virgin rats (by 57% and 40%), but only antalarmin was effective in pregnant rats (53% decrease). In vitro, measuring ACTH secretion from acutely dispersed anterior pituitary cells showed increased corticotroph sensitivity in pregnancy to CRH and to CRH augmentation by vasopressin, attributable to increased intracellular cAMP action. Hence, in late pregnancy, reduced anterior pituitary CRHR1 or V1b receptor expression did not impair corticotroph responses to CRH or vasopressin. Rather, diminished secretagogue secretion in vivo accounts for reduced action of stress levels of exogenous CRH or vasopressin alone; the late pregnancy attenuated ACTH secretory response to swim stress is deduced to be due to reduced vasopressin release by parvocellular paraventricular nuclei neurones.
Collapse
Affiliation(s)
- Shuaike Ma
- Centre for Integrative Physiology, School of Biomedical and Clinical Laboratory Sciences, College of Medicine and Veterinary Medicine, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, Scotland EH8 9XD, United Kingdom
| | | | | | | |
Collapse
|
7
|
Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001; 41:175-202. [PMID: 11264455 DOI: 10.1146/annurev.pharmtox.41.1.175] [Citation(s) in RCA: 110] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The neurohypophysial hormone arginine vasopressin (AVP) is a cyclic nonpeptide whose actions are mediated by the stimulation of specific G protein--coupled membrane receptors pharmacologically classified into V1-vascular (V1R), V2-renal (V2R) and V3-pituitary (V3R) AVP receptor subtypes. The random screening of chemical compounds and optimization of lead compounds recently resulted in the development of orally active nonpeptide AVP receptor antagonists. Potential therapeutic uses of AVP receptor antagonists include (a) the blockade of V1-vascular AVP receptors in arterial hypertension, congestive heart failure, and peripheral vascular disease; (b) the blockade of V2-renal AVP receptors in the syndrome of inappropriate vasopressin secretion, congestive heart failure, liver cirrhosis, nephrotic syndrome and any state of excessive retention of free water and subsequent dilutional hyponatremia; (c) the blockade of V3-pituitary AVP receptors in adrenocorticotropin-secreting tumors. The pharmacological and clinical profile of orally active nonpeptide vasopressin receptor antagonists is reviewed here.
Collapse
Affiliation(s)
- M Thibonnier
- Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio 44106-4951, USA.
| | | | | | | |
Collapse
|
8
|
Knepper MA, Valtin H, Sands JM. Renal Actions of Vasopressin. Compr Physiol 2000. [DOI: 10.1002/cphy.cp070313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Thibonnier M, Berti-Mattera LN, Dulin N, Conarty DM, Mattera R. Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. PROGRESS IN BRAIN RESEARCH 1999; 119:147-61. [PMID: 10074787 DOI: 10.1016/s0079-6123(08)61568-x] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Vasopressin (VP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by stimulation of specific G protein-coupled receptors (GPCRs) currently classified into V1-vascular (V1R), V2-renal (V2R) and V3-pituitary (V3R) VP receptors and OT receptors (OTR). The recent cloning of the different members of the VP/OT family of receptors now allows the extensive characterization of the molecular determinants involved in ligand binding and signal transduction pathways coupled to a given VP/OT receptor subtype in stably transfected mammalian cell lines. In this article, we review the present knowledge of the signal transduction pathways coupled to the different VP/OT receptor subtypes and we present new observations derived from the study of each human VP or OT receptor subtype stably expressed in CHO cells.
Collapse
Affiliation(s)
- M Thibonnier
- Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, OH 44106-4951, USA.
| | | | | | | | | |
Collapse
|
10
|
Watters JJ, Poulin P, Dorsa DM. Steroid hormone regulation of vasopressinergic neurotransmission in the central nervous system. PROGRESS IN BRAIN RESEARCH 1999; 119:247-61. [PMID: 10074792 DOI: 10.1016/s0079-6123(08)61573-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Vasopressinergic neurotransmission is intimately linked to steroid hormone signaling. Both arginine vasopressin (VP) and the extrahypothalamic VP V1a receptors are regulated by steroid hormones. Here, we present work that has been done in our laboratory, investigating mechanisms underlying steroid hormone effects on the expression of both VP and its primary receptor in the brain, the VP V1a receptor. Data on VP receptors, their coupling to second messenger pathways, their localization in brain, and their regulation by peptide exposure are discussed. We also cover the regulation of the V1a receptor by adrenal hormones, and the molecular basis of this effect. Evidence for the existence of other receptors for VP in the brain is presented. Lastly, the regulation of the VP peptide by gonadal hormones is discussed at the transcriptional level in the rodent brain. Finally, the potential significance of the 'cross-talk' between the vasopressinergic system and the steroid hormone system is addressed.
Collapse
Affiliation(s)
- J J Watters
- Department of Psychiatry, University of Washington, Seattle 98195, USA
| | | | | |
Collapse
|
11
|
Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1999; 449:251-76. [PMID: 10026814 DOI: 10.1007/978-1-4615-4871-3_34] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Vasopressin (AVP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by activation of specific G protein-coupled receptors (GPCRs) currently classified into V1-vascular (V1R), V2-renal (V2R) and V3-pituitary (V3R) AVP receptors and OT receptors (OTR). The cloning of the different members of the AVP/OT family of receptors now allows the extensive molecular pharmacological characterization of a single AVP/OT receptor subtype in stably transfected mammalian cell lines. The human V1-vascular (CHO-V1), V2-renal (CHO-V2), V3-pituitary (CHO-V3) and oxytocin (CHO-OT) receptors stably expressed in CHO cells display distinct binding profiles for 18 peptide and 5 nonpeptide AVP/OT analogs. Several peptide and nonpeptide compounds have a greater affinity for the V1R than AVP itself. V2R peptide agonists and antagonists tend to be non-selective ligands whereas nonpeptide V2R antagonists are potent and subtype-selective. None of the 22 AVP/OT analogs tested has a better affinity for the human V3R than AVP itself. Several peptide antagonists do not select well between V1R and OTR. These results underscore the need for developing specific and potent analogs interacting specifically with a given human AVP/OT receptor subtype.
Collapse
Affiliation(s)
- M Thibonnier
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-4951, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Abstract
Vasopressin has been implicated as a centrally acting endogenous antipyretic. However, in several species, including the pig, plasma vasopressin concentrations increase during the early stages of fever. This experiment investigated the effects of intravenous lysine vasopressin on core temperature in normal and febrile swine. Lysine vasopressin (20 microg/pig) stimulated cortisol release and induced a 60-min hypothermic episode in normal animals, although a 10-fold lower dose was without effect. The peptide also delayed the pyretic response to bacterial endotoxin (20 microg intravenously). It is speculated that the hypothermic action of circulating vasopressin may involve nitric oxide.
Collapse
Affiliation(s)
- R F Parrott
- Ministry of Agriculture, Fisheries, and Food, Department of Neurobiology, The Babraham Institute, Cambridge, United Kingdom.
| | | | | |
Collapse
|
13
|
Evans RG, Bergström G, Lawrence AJ. Effects of the vasopressin V1 agonist [Phe2,Ile3,Orn8]] vasopressin on regional kidney perfusion and renal excretory function in anesthetized rabbits. J Cardiovasc Pharmacol 1998; 32:571-81. [PMID: 9781925 DOI: 10.1097/00005344-199810000-00009] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
To test whether renal V1-receptors selectively influence blood flow in the renal medulla, we compared the effects of infusion of [Phe2,Ile3,Orn8]vasopressin (3-30 ng/kg/min) by the intravenous, renal arterial, and renal medullary interstitial routes in anesthetized rabbits. Intravenous [Phe2,Ile3,Orn8]vasopressin (30 ng/kg/min) reduced renal medullary perfusion (MBF) by 36 +/- 5% but did not significantly affect cortical perfusion (CBF). MBF was also reduced with the renal arterial (35 +/- 5%) and renal medullary interstitial (40 +/- 7%) routes but, in contrast to the intravenous infusion, CBF was also reduced, by 21 +/- 3% and 15 +/- 3%, respectively. Urine flow and sodium excretion were increased by [Phe2,Ile3,Orn8]vasopressin, and with direct intrarenal administration, this effect was similar for both the infused (left) and noninfused (right) kidneys. After a 20-min renal medullary interstitial infusion of [3H]norepinephrine, radiolabel concentration was approximately fivefold greater in the left medulla than in the left cortex. We conclude that [Phe2,Ile3,Orn8]vasopressin acts on V1-receptors to alter regional kidney blood flow and tubular salt and water handling. The V1-receptors involved are almost certainly within the kidney itself, but given the contrasting effects of the different infusion routes on MBF and CBF, we cannot exclude the possibility that some of the observed effects of [Phe2,Ile3,Orn8]vasopressin are mediated by activation of extra-renal V1-receptors.
Collapse
Affiliation(s)
- R G Evans
- Department of Physiology, Monash University, Clayton, Victoria, Australia
| | | | | |
Collapse
|
14
|
Vellucci SV, Parrott RF. Vasopressin and oxytocin gene expression in the porcine forebrain under basal conditions and following acute stress. Neuropeptides 1997; 31:431-8. [PMID: 9413019 DOI: 10.1016/s0143-4179(97)90036-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This study, the first using the pig, examined expression of mRNAs for vasopressin (VP), oxytocin (OT), preproenkephalin (PENK) and pro-opiomelanocortin (POMC) in the forebrain, and of POMC and prolactin in the pituitary. High basal expression of VP and OT mRNAs was present in the paraventricular (PVN) and supraoptic (SON) nuclei. In the PVN, VP was found in magnocellular regions whereas OT was also seen in the parvocellular portion; the distribution of VP and OT mRNAs in the SON was as reported in other species. The suprachiasmatic nucleus contained VP mRNA but only OT message was present in the dorsomedial SON, a structure peculiar to swine. Gene expression for PENK occurred in the caudate putamen (CPu), for POMC in the mediobasal hypothalamus (MBH) and for prolactin and POMC in the hypophysis. Following restraint, VP message increased in the magnocellular PVN, as did PENK in the CPu and POMC in the MBH.
Collapse
Affiliation(s)
- S V Vellucci
- MAFF Welfare and Behaviour Laboratory, Department of Neurobiology, Babraham Institute, Cambridge, UK
| | | |
Collapse
|
15
|
Watters JJ, Wilkinson CW, Dorsa DM. Glucocorticoid regulation of vasopressin V1a receptors in rat forebrain. BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1996; 38:276-84. [PMID: 8793116 DOI: 10.1016/0169-328x(95)00345-s] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Vasopressin V1a receptors (V1aRs) are expressed in the septum of the rat brain where they are thought to mediate several of the physiologic and behavioral effects of this neuropeptide. We have investigated the effects of adrenal steroids on forebrain V1aRs. Rats were bilaterally adrenalectomized (ADX) and hormone replaced with either corticosterone (CORT), dexamethasone (DEX) or aldosterone (ALDO) at different concentrations. V1aR mRNA was evaluated using in situ hybridization, and V1aR binding site density was quantified using a specific iodinated V1aR antagonist [125I]d(CH2)5Sar7-AVP (125I-SAVP). V1aR density in the dorsolateral septum and the bed nucleus of the stria terminalis (BNST) decreased significantly with adrenalectomy, and 5 micrograms/100 g b.wt. of DEX was able to restore V1aR binding to levels comparable to those of sham operated controls in both regions. ALDO replacement also elevated V1aR binding in the BNST but not in the septum. In ADX animals given corticosterone in their drinking water, V1aR mRNA levels detected by in situ hybridization increased significantly over the ADX rats given saline. In order to understand the molecular basis of this effect, a putative genomic clone encoding the rat V1aR was isolated, and sequence analysis of the 5' flanking region has revealed the presence of several putative glucocorticoid response elements (GREs). Gel retardation assays were performed using these putative GREs, and two appear to be active in protein binding in glucocorticoid receptor containing nuclear extracts. The glucocorticoid effects on V1aR mRNA and binding, and the presence of putative active GREs in the promoter of the V1aR gene strongly implicate a role for adrenal steroids in the regulation of V1a receptor gene expression in glucocorticoid receptor and/or mineralocorticoid receptor expressing tissues.
Collapse
Affiliation(s)
- J J Watters
- Department of Pharmacology, University of Washington, Seattle 98195, USA
| | | | | |
Collapse
|
16
|
Watters JJ, Swank MW, Wilkinson CW, Dorsa DM. Evidence for glucocorticoid regulation of the rat vasopressin V1a receptor gene. Peptides 1996; 17:67-73. [PMID: 8822512 DOI: 10.1016/0196-9781(95)02085-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
WRK-1 cells express vasopressin V1a receptors. Twenty-four-hour treatment of these cells with dexamethasone (DEX) resulted in an increase in [3H]AVP binding that was maximal at 12 h, and could be blocked by addition of RU 38486. The increases in [3H]AVP binding were paralleled by increases in V1a receptor mRNA. The in vivo effects of glucocorticoids (GCs) on V1a receptor binding in hepatic tissue were also investigated in adrenalectomized and hormone-replaced rats given either DEX or aldosterone (ALDO). DEX effectively increased V1a receptor binding site density whereas ALDO had no effect. The DEX effects on V1a receptor mRNA and binding strongly implicate glucocorticoids in the regulation of V1a receptor gene expression.
Collapse
Affiliation(s)
- J J Watters
- Department of Psychology, Furman University, Greenville, SC 29613, USA
| | | | | | | |
Collapse
|
17
|
Abstract
1. Vasopressin, a mammalian neurohypophysial peptide hormone, has diverse physiological actions. 2. Pharmacological studies, using a range of mammalian tissues, have identified three subtypes of vasopressin receptor. 3. The V1a subtype of vasopressin receptor is widely distributed and mediates many central and peripheral actions of vasopressin. 4. The development of subtype-selective vasopressin analogues has provided valuable tools for pharmacological and physical studies of the V1a receptor protein. 5. Pharmacological differences indicate species heterogeneity in the characteristics of V1a receptors and in the expression of hepatic V1a receptors. 6. The cloning of neurohypophysial hormone receptor proteins allows structural and functional comparison of the V1a vasopressin receptors with other G-protein-coupled receptors.
Collapse
Affiliation(s)
- J Howl
- School of Biochemistry, University of Birmingham, Edgbaston, U.K
| | | |
Collapse
|